Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight
New York, Jan 6, 2026, 10:40 EST — Regular session Novo Nordisk A/S shares listed in New York as ADRs climbed about 4.7% to $57.71 on Tuesday, after touching an intraday high of $58.14. The move extends a rebound sparked by the U.S. rollout of a pill version of Wegovy, a franchise that has become central to how investors value the Danish drugmaker’s growth story. The launch matters now because the obesity market is shifting from a supply-driven boom to a fight over price, convenience and who pays. Novo needs the pill to widen demand without triggering a margin-eroding price